M.D. Anderson Center Will Consolidate Faculty Offices in New Building in 2000

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 10
Volume 7
Issue 10

HOUSTON--A new faculty center will allow M.D. Anderson Cancer Center to consolidate faculty offices currently located in several buildings on its main campus. The new facility, approved by the University of Texas System Board of Regents last August, will be constructed on the south side of Holcombe Boulevard, adjacent to the Jesse H. Jones Rotary House International patient/family hotel and directly across the street from M.D. Anderson’s main clinic and hospital complex (figure).

HOUSTON--A new faculty center will allow M.D. Anderson Cancer Center to consolidate faculty offices currently located in several buildings on its main campus. The new facility, approved by the University of Texas System Board of Regents last August, will be constructed on the south side of Holcombe Boulevard, adjacent to the Jesse H. Jones Rotary House International patient/family hotel and directly across the street from M.D. Anderson’s main clinic and hospital complex (figure).

The $45.4 million faculty center will include 13 floors for physicians’ offices and support functions as well as a food court, copy center, mail services, and a sky bridge that connects the building to the Rotary House. An existing bridge links Rotary House to M.D. Anderson’s clinic and hospital buildings.

Construction is scheduled to begin in the spring of 1999, with completion expected by the fall of 2000.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content